E2451_1211C_HER2_4B5_Breast_and_Gastric_Interpretation_Guide-05.indd2-115-Dec-20115:47PM 23 Introduction VENTANAanti-HER2/neu(4B5)RabbitMonoclonalPrimary Antibody[VENTANAHER2(4b5)]isintended orthesemi- quantitativedetectiono HER2antigeninsectionso ormalin- ...
贝登医疗HER-2/NEU抗体 VENTANA anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody医疗器械注册证主要信息:注册证编号为国食药监械(进)字2012第3402756号、注册人名称为Roche Diagnostics GmbH。
HER-2/NEU抗体试剂(免疫组织化学法)VENTANA anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody,HER-2/NEU抗体含有足够供50次试验的试剂。1瓶5mL的HER-2/NEU抗体含有大约30ug(6ug/mL)的兔单克隆抗体,可直接对抗组织中存在的HER-2/neu蛋白。该抗体用含有载体蛋白和
HER2 scoring proficiency of pathologists was high for both assays when assessed on ASCO/CAP binary HER2-negative and -positive status, irrespective of training (4B5: 魏 = 0.96, ORA =98.9.%; HcT: 魏 = 0.84, ORA = 94.3%) Concordance per ORA for the new 3-tier classification (HER2 IHC ...
肿瘤学巨头罗氏(Roche)近日宣布推出新的VENTANA HER2 Dual ISH DNA Probe Cocktail assay(VENTANA HER2双原位杂交DNA探针鸡尾酒检测法),用于检测乳腺癌和胃癌中的HER2生物标志物。HER2(人表皮生长因子受体2)是乳腺癌和胃癌的重要生物标志物,其检测和抑制有助于更有效地治疗这些侵袭性癌症。在全球范围内,每年诊断近210...
(FDA) for the VENTANA Companion Algorithm Progesterone Receptor (PR) (1E2) image analysis application used with the VENTANA iScan Coreo Au scanner running VIRTUOSO software. This announcement comes on the heels of two other FDA clearances Ventana recently announced...
Ventana的上市后商业化运营能力远远超过Dako,成为目前中国伴随诊断的头牌。伴随诊断覆盖的靶点囊括了HER2、PD-L1、EGFR、C-KIT、ALK、MMR等,临床使用可根据抗体染色结果将肿瘤分成几种不同类型,每种类型都有不同预后和疾病转归,从而对患者治疗预后做出指导性判断。
PATHWAYHER-2/neu(4B5)with iVIEWDABdetection BreastCarcinoma 40Xmagnifcation HER2DualISH INFORMHER2DualISHDNAProbe Cocktail with ultraView SISH DNP Detection kit and ultraView Red ISH DIG Detection kit. Breast carcinoma with low-level ampli cation of HER2 ...
HER-2/NEU抗体试剂(免疫组织化学法) VENTANA anti-HER2 /neu (4B5) Rabbit Monoclonal Primary Antibody,HER-2/NEU抗体含有足够供50次试验的试剂。1瓶 5ml的HER-2/NEU抗体含有大约30ug(6ug/ml)的兔单克隆抗体,可直接对抗组织中存在的HER-2/neu蛋白。该抗体用含有载体蛋白
HER2 FISHHercepTest4B5Overexpression of HER2 receptor/protein due to ERBB2 (HEK2lneu) gene amplification occurs in 15% to 20% of breast cancers. It is a strong prognostic factor associated with an aggressive disease course and an independent predictor of time to relapse and overall survival.1...